Tratamiento de pénfigo vulgar grave resistente con rituximab
- 31 January 2006
- journal article
- case report
- Published by Elsevier BV in Actas Dermo-Sifiliograficas
- Vol. 97 (1), 48-51
- https://doi.org/10.1016/s0001-7310(06)73348-8
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Infliximab in the management of severe pemphigus vulgarisBritish Journal of Dermatology, 2005
- Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab)Journal of the American Academy of Dermatology, 2004
- Follicular Non-Hodgkin's Lymphoma with Refractory Paraneoplastic Pemphigus: Case Report with Review of Novel Treatment ModalitiesLeukemia & Lymphoma, 2004
- Rituximab in autoimmune diseasesBiomedicine & Pharmacotherapy, 2004
- Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlationsJournal of the American Academy of Dermatology, 2004
- Treatment of Refractory Pemphigus Vulgaris With Rituximab (Anti-CD20 Monoclonal Antibody)Archives of Dermatology, 2004
- Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximabBritish Journal of Dermatology, 2003
- Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab)Clinical and Experimental Dermatology, 2003
- Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab)British Journal of Dermatology, 2003
- Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effectsBlood, 2002